


■ New Zealand  
■ Australia  
■ Canada  
■ USA



■ Denmark  
■ Finland  
■ France  
■ United Kingdom

**Appendix 4 (as supplied by the authors): Mortality of Prostate Cancer in selected countries, 1975-2012, showing changes related to PSA screening implementation (data from IARC Globocan).**

Appendix to: Dickinson J, Shane A, Tonelli M, et al. Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. *CMAJ Open* 2016. DOI:10.9778/cmajo.20140079.